NAD+ vs 5-Amino-1MQ: What the Research Shows

Research Use Only. The materials described here are laboratory reagents supplied strictly for in vitro and preclinical research. They are not medicines, not supplements and not food. Not for human or veterinary use.

NAD+ and 5-amino-1MQ come up together often in laboratory shopping lists, and it is easy to see why. Both are studied in the context of cellular nicotinamide adenine dinucleotide metabolism. What is less obvious is that they sit at opposite ends of that pathway. One is the cofactor itself. The other is a small molecule tool used to inhibit an enzyme that consumes a precursor of that cofactor. This article compares the two as research materials, summarises what the preclinical literature has reported for each, and outlines the handling differences a laboratory will notice in practice.

What is NAD+ and what is 5-amino-1MQ

Nicotinamide adenine dinucleotide in its oxidised form, written NAD+, is a coenzyme present in every living cell. It shuttles electrons in redox reactions across glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation, and it also serves as a consumed substrate for enzyme families such as the sirtuins, PARPs and CD38. Because it is both an electron carrier and a substrate that gets used up, cellular NAD+ levels are a recurring readout in metabolic and ageing research. As a research material it is supplied as a stable white powder or as a prepared research solution.

5-Amino-1MQ, or 5-amino-1-methylquinolinium, is something quite different. It is a small synthetic methylquinolinium compound developed as a selective inhibitor of nicotinamide N-methyltransferase, usually abbreviated NNMT. NNMT methylates nicotinamide to form 1-methylnicotinamide. Since nicotinamide is a salvage-pathway precursor of NAD+, the working hypothesis behind NNMT inhibitors in the literature is that blocking that methylation step leaves more nicotinamide available for NAD+ synthesis inside the cell. So NAD+ is the endpoint molecule, while 5-amino-1MQ is a pathway probe aimed upstream of it.

Where they sit in the research literature

The two compounds have distinct literature footprints, and it is worth reading them separately rather than as interchangeable options.

Reported preclinical areas for NAD+ and its precursors

• Age-related changes in tissue NAD+ availability, measured across organs in rodent models.
• Mitochondrial oxidative metabolism and gene expression profiles in skeletal muscle and liver of aged mice.
• Sirtuin and PARP enzyme activity, which depend on NAD+ as a consumed substrate.
• Energy metabolism, insulin sensitivity and plasma lipid measurements in rodent models given NAD+ precursors such as nicotinamide mononucleotide.
• Neurodegeneration models, where systematic reviews have collected preclinical work on NAD+ precursors in murine Alzheimer models.

Reported preclinical areas for 5-amino-1MQ and NNMT inhibition

• Enzyme selectivity work, comparing methylquinolinium scaffolds against structurally related SAM-dependent methyltransferases and NAD salvage enzymes.
• Membrane permeability characterisation using parallel artificial membrane and Caco-2 cell assays.
• Intracellular metabolite measurements in cultured adipocytes, including 1-methylnicotinamide, NAD and S-adenosyl-l-methionine.
• Lipogenesis readouts in cultured adipocyte lines.
• Body composition and adipocyte size measurements in diet-induced obese mouse models.

A useful way to hold the difference in mind: the NAD+ literature is largely about supplying or restoring a cofactor, while the 5-amino-1MQ literature is largely about inhibiting an enzyme and then measuring what happens to the cofactor pool downstream. That distinction shapes what a study design with either material tends to look like.

Chemistry and notes at a glance

• NAD+. Nicotinamide adenine dinucleotide, oxidised form. A dinucleotide built from an adenine nucleotide and a nicotinamide nucleotide joined through a pyrophosphate bridge. Molecular formula C21H27N7O14P2, molecular weight approximately 663.4 g/mol. Endogenous, non-synthetic, water soluble, hygroscopic in powder form.
• 5-Amino-1MQ. 5-amino-1-methylquinolinium, typically supplied as an iodide salt. A small synthetic quinolinium heterocycle, molecular weight of the cation approximately 159.2 g/mol. Fully synthetic, not an endogenous metabolite, and reported in the source literature to be membrane permeable.
• Point of contact between them. Nicotinamide. NNMT methylates it away from the salvage route, and NAD+ synthesis draws on it. That single shared node is the whole reason these two compounds are discussed side by side.
• Formats. NAD+ is common as lyophilised powder in vials. 5-amino-1MQ is available both as a research solution and in capsule format for laboratory inventory purposes, a difference covered in more detail in our note on 5-amino-1MQ solution versus capsules.

Why the research use only label matters

Neither of these materials holds a marketing authorisation as a medicine anywhere in the European Union. NAD+ occupies a slightly confusing space in public conversation because nicotinamide and related vitamers appear in the food supplement world, but a research-grade NAD+ reagent vial is not a food supplement and is not manufactured, tested or labelled as one. 5-Amino-1MQ is more clear-cut: it is an investigational small molecule that has not completed any regulatory approval process, and published work on it is preclinical, meaning cell culture and animal models.

Under EU law, presenting a chemical reagent with a health or therapeutic claim, or with any instruction implying human or veterinary administration, moves it out of the REACH reagent framework and into medicinal product territory under Directive 2001/83/EC. That is why every description on this site stays with what the published literature reports in cells and animals, in the third person, and never crosses into use guidance. It is also why the disclaimer appears at both ends of this article rather than buried in a footer.

One practical note on the 5-amino-1MQ literature specifically. The most-cited paper describing methylquinolinium NNMT inhibitors reports reduced body weight and white adipose mass in diet-induced obese mice. Those are animal outcomes in a controlled study, published as target validation for a possible future drug programme. They are not evidence about people, no human trial has established anything comparable, and they should not be read as a claim about what the compound does outside that model.

Handling and storage for researchers

The two materials behave differently on the bench, and the differences are worth planning for before a study starts.

• NAD+ powder is hygroscopic and is generally kept sealed, dry and cold, protected from moisture ingress. Aqueous solutions of NAD+ are known to be less stable than the dry form and are usually prepared close to the time of the assay rather than stored long term.
• 5-Amino-1MQ as a small synthetic salt is comparatively robust in the dry state, though standard practice is still cool, dry and protected from light.
• Solvent choice matters for reproducibility. Aqueous reconstitution is standard for many laboratory workflows, and the trade-offs are set out in our comparison of bacteriostatic water versus acetic acid.
• Freeze-thaw cycling is a common and avoidable source of variability. Aliquoting on first reconstitution is the usual mitigation. General principles are collected in our peptide storage and stability guide.
• Identity and purity should be checked against the certificate of analysis for the specific lot before any quantitative work, since assigning a result to a compound requires knowing what was actually in the vial.

Pure Chems supplies both materials as research reagents for laboratory use. You can view the current NAD+ 400mg research vial and the 5-amino-1MQ 50mg research vial in the catalogue.

Frequently asked questions

Are NAD+ and 5-amino-1MQ the same kind of research material?

No. NAD+ is an endogenous coenzyme supplied as a reagent, while 5-amino-1MQ is a synthetic enzyme inhibitor targeting NNMT. They are discussed together because both intersect with NAD metabolism, but they are used to ask different experimental questions.

Is either compound approved as a medicine?

Neither holds a marketing authorisation as a medicinal product in the EU or, to our knowledge, elsewhere. 5-Amino-1MQ is an investigational compound whose published record is preclinical. NAD+ appears in nutrition contexts as a related vitamer conversation, but a research-grade NAD+ reagent is not an approved medicine and is not a supplement.

Is 5-amino-1MQ legal to buy for research in the EU?

5-Amino-1MQ is not a controlled substance in the European Union and can be supplied as a laboratory chemical for research use, subject to the supplier and the buyer both treating it as a reagent rather than a consumer product. National rules vary and can change, so an institution should confirm its own position. NAD+ is likewise handled as a laboratory chemical in this context. Nothing here is legal advice.

Is either compound on the WADA prohibited list?

Neither NAD+ nor 5-amino-1MQ appears by name on the World Anti-Doping Agency prohibited list as published. However, WADA operates catch-all categories covering substances with no current regulatory approval for human therapeutic use, and 5-amino-1MQ as an investigational compound would fall within the scope of that kind of provision. The list is revised annually, so the current edition is the only reliable source.

Which one is studied more?

NAD+ and its precursors have by far the larger literature, spanning decades of biochemistry plus a substantial recent body of ageing and metabolic work. 5-Amino-1MQ has a much smaller and newer footprint, concentrated in NNMT inhibitor chemistry and adipocyte metabolism from roughly 2017 onward. Anyone designing a study should expect less published methodology to lean on for the latter.

Key takeaways

• NAD+ is the cofactor. 5-Amino-1MQ is an inhibitor of NNMT, an enzyme that diverts a NAD+ precursor. They meet at nicotinamide.
• The NAD+ preclinical literature centres on cofactor availability, mitochondrial metabolism and ageing models in rodents. The 5-amino-1MQ literature centres on enzyme selectivity, permeability and adipocyte metabolite readouts.
• All published findings for both are in vitro or in animal models. Neither is an approved medicine, and neither is for human or veterinary use.
• NAD+ powder is hygroscopic and its solutions are less stable than the dry form, so aliquoting and prompt use matter more than with the synthetic salt.
• Lot-specific certificate of analysis review should precede any quantitative comparison between the two.

References

References sourced via PubMed.

1. Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 2017. https://doi.org/10.1016/j.bcp.2017.11.007 · https://pubmed.ncbi.nlm.nih.gov/29155147/
2. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai S. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism, 2016. https://doi.org/10.1016/j.cmet.2016.09.013 · https://pubmed.ncbi.nlm.nih.gov/28068222/
3. Alghamdi M, Braidy N. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach. Journal of Alzheimer's Disease, 2024. https://doi.org/10.3233/JAD-231277 · https://pubmed.ncbi.nlm.nih.gov/39422945/

For deeper single-compound coverage, see our standalone notes on NAD+ research and 5-amino-1MQ research, and the wider mitochondrial-derived peptides overview.

Disclaimer: Research Use Only. All materials described in this article are laboratory reagents intended solely for in vitro and preclinical research by qualified personnel. They are not medicinal products, dietary supplements or cosmetics, and no therapeutic or health claim is made or implied. Not for human or veterinary use. Nothing here is medical or legal advice.